Background:Tuberculosis(TB)remains a leading cause of mortality worldwide,particularly in developing nations.Currently,available diagnostic methods are often too costly or insufficiently sensitive for effective use in...Background:Tuberculosis(TB)remains a leading cause of mortality worldwide,particularly in developing nations.Currently,available diagnostic methods are often too costly or insufficiently sensitive for effective use in low-and middle-income countries.Developing a rapid,convenient,and accurate method for detecting the Mycobacterium tuberculosis complex(MTBC)is crucial to curtail the spread of TB.Methods:Primers and probes targeting conserved regions of IS1081 were designed,and the RNase P gene was introduced as an internal control to prevent false-negative results.M.tuberculosis control was used to optimize the reaction temperature.Additionally,we calculated and compared the limit of detection,specificity,and coincidence rate between this platform and the TaqMan real-time fluorescence quantification method(RT-qPCR)using two sets of national reference panels and 10 strains of MTBC.Results:An on-site MTBC-multiplex recombinase polymerase amplification(MTBC-mRPA)platform was established,with detection within 30 min over a broad temperature range(25℃-45℃).Probit analysis estimated a 95% limit of detection of 557.16(95% confidence interval:406.76-1062.67)bacteria/mL(p<0.0001),close to the limit of detection of 461.84(95% confidence interval:342.55-881.57)bacteria/mL(p<0.0001)of qPCR.The platform differentiated between non-tuberculous mycobacteria and other common respiratory bacteria,showing 100% specificity.The coincidence rate between multiplex real-time recombinase polymerase amplification(RT-mRPA)and RT-qPCR was 100%,indicating substantial similarity.Conclusion:A simple,rapid,and visual MTBC-mRPA platform coupled with rapid DNA extraction was developed for sensitive and specific detection of MTBC,especially suitable for on-site screening of TB in low-resource settings.展开更多
<b><span style="font-family:Verdana;">Objective: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">To under...<b><span style="font-family:Verdana;">Objective: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">To understand the distribution of drug susceptibility test results of opportunistic infections of tuberculosis and non-tuberculous bacilli in AIDS patients. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">The AIDS patients who were hospitalized in our hospital from January 2016 to June 2019 were collected as the research objects, and patients with opportunistic tuberculosis and non-tuberculous bacilli from AIDS patients were screened for drug susceptibility tests, and the distribution characteristics of drug susceptibility were analyzed. </span><b><span style="font-family:Verdana;">Results: </span></b><span><span style="font-family:Verdana;">179 strains of tuberculosis and non-tuberculous mycobacteria were isolated from the specimens of AIDS patients, including 135 cases of tuberculosis mycobacteria and 44 cases of non-tuberculous mycobacteria. In the results of the drug susceptibility test, most strains of </span><i></i></span><i><i><span style="font-family:Verdana;">Mycobacterium tuberculosis</span></i><span></span></i><span style="font-family:Verdana;"> showed sensitivity to commonly used drugs, and a few strains showed resistance;most strains </span></span><span style="font-family:Verdana;">of non-tuberculous mycobacteria showed resistance, and a few strains showed</span><span style="font-family:Verdana;"> sensitivity. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span><span style="font-family:Verdana;">AIDS opportunistic infection of </span><i></i></span><i><i><span style="font-family:Verdana;">Mycobacterium tuberculosis</span></i><span></span></i><span style="font-family:Verdana;"> and non-tuberculous mycobacteria have significant differences in drug sensitivity test results. Timely detection and analysis are of great significance to the diagnosis and treatment of the disease.</span>展开更多
Objective: To compare the yield from Gastric lavage (GL) and Broncho alveolar lavage (BAL) samples in adult patients suspected case of Tuberculosis but not producing sputum. Methodology: 80 adults with suspected case ...Objective: To compare the yield from Gastric lavage (GL) and Broncho alveolar lavage (BAL) samples in adult patients suspected case of Tuberculosis but not producing sputum. Methodology: 80 adults with suspected case of tuberculosis but not producing sputum were recruited. 72 patients were then subjected to one gastric lavage followed by Broncho-alveolar lavage in the same morning. The collected samples were subjected to GeneXpert MTB/RIF assay. Result: Of the 72 patients samples, the mean age was 38.6 years. 41 (56.9%) were male and 31 (43.1%) were female. History of TB contact was present in 25 (34.7%) patients. 37 (51.4%) patients had GeneXpert MTB/RIF positive on BAL and/or GL samples. The GeneXpert MTB/RIF of BAL fluid was positive on 35 (48.6%), which was not significantly greater than that for specimens from GL, which was 28 (38.9%) (p > 0.05). In 26 (36.1%) cases, GeneXpert MTB/RIF was positive in both BAL and GL samples. Conclusion: This study showed the yield of GeneXpert MTB/RIF in GL was comparable to BAL to detect Mycobacterium tuberculosis complex. Patients who can’t produce sputum, GL can be a good alternative to BAL to detect Mycobacterium tuberculosis complex in resource poor areas and patients who do not tolerate Bronchoscopy.展开更多
基金supported by the Natural Science Foundation of Jiangsu Province(Grant No.BK20200682).
文摘Background:Tuberculosis(TB)remains a leading cause of mortality worldwide,particularly in developing nations.Currently,available diagnostic methods are often too costly or insufficiently sensitive for effective use in low-and middle-income countries.Developing a rapid,convenient,and accurate method for detecting the Mycobacterium tuberculosis complex(MTBC)is crucial to curtail the spread of TB.Methods:Primers and probes targeting conserved regions of IS1081 were designed,and the RNase P gene was introduced as an internal control to prevent false-negative results.M.tuberculosis control was used to optimize the reaction temperature.Additionally,we calculated and compared the limit of detection,specificity,and coincidence rate between this platform and the TaqMan real-time fluorescence quantification method(RT-qPCR)using two sets of national reference panels and 10 strains of MTBC.Results:An on-site MTBC-multiplex recombinase polymerase amplification(MTBC-mRPA)platform was established,with detection within 30 min over a broad temperature range(25℃-45℃).Probit analysis estimated a 95% limit of detection of 557.16(95% confidence interval:406.76-1062.67)bacteria/mL(p<0.0001),close to the limit of detection of 461.84(95% confidence interval:342.55-881.57)bacteria/mL(p<0.0001)of qPCR.The platform differentiated between non-tuberculous mycobacteria and other common respiratory bacteria,showing 100% specificity.The coincidence rate between multiplex real-time recombinase polymerase amplification(RT-mRPA)and RT-qPCR was 100%,indicating substantial similarity.Conclusion:A simple,rapid,and visual MTBC-mRPA platform coupled with rapid DNA extraction was developed for sensitive and specific detection of MTBC,especially suitable for on-site screening of TB in low-resource settings.
文摘<b><span style="font-family:Verdana;">Objective: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">To understand the distribution of drug susceptibility test results of opportunistic infections of tuberculosis and non-tuberculous bacilli in AIDS patients. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">The AIDS patients who were hospitalized in our hospital from January 2016 to June 2019 were collected as the research objects, and patients with opportunistic tuberculosis and non-tuberculous bacilli from AIDS patients were screened for drug susceptibility tests, and the distribution characteristics of drug susceptibility were analyzed. </span><b><span style="font-family:Verdana;">Results: </span></b><span><span style="font-family:Verdana;">179 strains of tuberculosis and non-tuberculous mycobacteria were isolated from the specimens of AIDS patients, including 135 cases of tuberculosis mycobacteria and 44 cases of non-tuberculous mycobacteria. In the results of the drug susceptibility test, most strains of </span><i></i></span><i><i><span style="font-family:Verdana;">Mycobacterium tuberculosis</span></i><span></span></i><span style="font-family:Verdana;"> showed sensitivity to commonly used drugs, and a few strains showed resistance;most strains </span></span><span style="font-family:Verdana;">of non-tuberculous mycobacteria showed resistance, and a few strains showed</span><span style="font-family:Verdana;"> sensitivity. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span><span style="font-family:Verdana;">AIDS opportunistic infection of </span><i></i></span><i><i><span style="font-family:Verdana;">Mycobacterium tuberculosis</span></i><span></span></i><span style="font-family:Verdana;"> and non-tuberculous mycobacteria have significant differences in drug sensitivity test results. Timely detection and analysis are of great significance to the diagnosis and treatment of the disease.</span>
文摘Objective: To compare the yield from Gastric lavage (GL) and Broncho alveolar lavage (BAL) samples in adult patients suspected case of Tuberculosis but not producing sputum. Methodology: 80 adults with suspected case of tuberculosis but not producing sputum were recruited. 72 patients were then subjected to one gastric lavage followed by Broncho-alveolar lavage in the same morning. The collected samples were subjected to GeneXpert MTB/RIF assay. Result: Of the 72 patients samples, the mean age was 38.6 years. 41 (56.9%) were male and 31 (43.1%) were female. History of TB contact was present in 25 (34.7%) patients. 37 (51.4%) patients had GeneXpert MTB/RIF positive on BAL and/or GL samples. The GeneXpert MTB/RIF of BAL fluid was positive on 35 (48.6%), which was not significantly greater than that for specimens from GL, which was 28 (38.9%) (p > 0.05). In 26 (36.1%) cases, GeneXpert MTB/RIF was positive in both BAL and GL samples. Conclusion: This study showed the yield of GeneXpert MTB/RIF in GL was comparable to BAL to detect Mycobacterium tuberculosis complex. Patients who can’t produce sputum, GL can be a good alternative to BAL to detect Mycobacterium tuberculosis complex in resource poor areas and patients who do not tolerate Bronchoscopy.
